Multiple Sclerosis Banner

Featured Article

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Latest

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

Cases of acalculous cholecystitis and a single case of acute coronary syndrome associated with the use of alemtuzumab are reported.

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.

Are Vaccines Associated With Multiple Sclerosis Relapse?

Are Vaccines Associated With Multiple Sclerosis Relapse?

Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.

Sign Up for Free e-newsletters

CME Focus